𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Squamous cell carcinoma of the head and neck in never smoker–never drinkers: A descriptive epidemiologic study

✍ Scribed by Kristina R. Dahlstrom; Jarrod A. Little; Mark E. Zafereo; Margaret Lung; Qingyi Wei; Erich M. Sturgis

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
190 KB
Volume
30
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background.

While the attributed risk factors for the vast majority of patients with squamous cell carcinoma of the head and neck (SCCHN) are smoking and alcohol abuse, there appears to be a rising proportion of SCCHN patients who report no significant smoking or drinking history. This study reports the demographic and potential risk factors of a large series of never smoker–never drinker (NSND) patients.

Methods.

All subjects were participants in a prospective epidemiologic study of incident SCCHN. We obtained demographic data, clinical characteristics, and potential etiologic factors for 172 NSND patients and 1131 ever smoker–ever drinker (ESED) patients.

Results.

NSND patients were more likely to be female and to present at extremes of age, but overall were significantly younger than ESED patients. NSND patients had a higher proportion of oral cavity and oropharyngeal cancers than ESED patients had. Eleven percent of NSND patients (17% of NSND men) reported regular use of noncigarette tobacco products or marijuana, 41% (45% of NSND women) reported regular environmental exposure to tobacco smoke, 24% (36% of NSND men) reported regular occupational exposures to carcinogens/toxins, and 30% had a history of gastroesophageal reflux disease. More than half the NSND patients with an oropharyngeal primary were serologically positive for human papillomavirus type 16.

Conclusion.

NSND patients with SCCHN are commonly young women with oral tongue cancer, elderly women with gingival/buccal cancer, or young to middle‐aged men with oropharyngeal cancer. While several exposures studied may be important to the etiology of a subset of these cancers in NSND patients, it is likely that no single known factor is responsible for a majority of SCCHN in NSNDs. © 2007 Wiley Periodicals, Inc. Head Neck, 2008

📜 SIMILAR VOLUMES

Never-smokers, never-drinkers: Unique cl
Never-smokers, never-drinkers: Unique clinical subgroup of young patients with head and neck squamous cell cancers
✍ Stephen L. Harris; Randall J. Kimple; D. Neil Hayes; Marion E. Couch; Julian G. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

## Abstract ## Background. Young patients represent an increasing subgroup with head and neck cancer. ## Methods. Patients between 18 and 39 years of age with newly diagnosed and previously untreated squamous cell cancers were identified. ## Results. Seventy‐eight patients met the selection cr

Loss of heterozygosity studies in squamo
Loss of heterozygosity studies in squamous cell carcinomas of the head and neck
✍ David T. Ransom; J. Helen Leonard; John H. Kearsley; Gavin R. Turbett; Kathy Hee 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 800 KB

Background. Loss of heterozygosity (LOH) studies have been pivotal in identifying tumor suppressor genes involved in the pathogenesis of a number of cancers. In squamous cell carcinomas of the head and neck region (SCCHN), LOH studies using the Southern blot technique are scarce. Methods. SCCHNs we

Targeted therapies in squamous cell carc
Targeted therapies in squamous cell carcinoma of the head and neck
✍ Kathryn A. Gold; Ho-Young Lee; Edward S. Kim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 3 views

## Abstract Head and neck cancer is a challenging disease that is expected to account for greater than 500,000 new cases worldwide in 2008. Toxicity has impeded advances in chemotherapy and radiation for head and neck cancer, and the prognosis for patients with recurrent and/or metastatic disease r

A phase II study of adriamycin in previo
A phase II study of adriamycin in previously untreated squamous cell carcinoma of the head and neck
✍ Melody A. Cobleigh; James H. Hill; Patricia A. Gallagher; Lawrence J. Kukla; Tho 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB 👁 2 views

Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m\* at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 eval